BGE-117, 4mg + BGE-117, 12mg
Phase 2Withdrawn 2 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Posthemorrhagic Anemia
Conditions
Acute Posthemorrhagic Anemia
Trial Timeline
Apr 1, 2022 → Jul 1, 2024
NCT ID
NCT05152641About BGE-117, 4mg + BGE-117, 12mg
BGE-117, 4mg + BGE-117, 12mg is a phase 2 stage product being developed by BioAge Labs for Acute Posthemorrhagic Anemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05152641. Target conditions include Acute Posthemorrhagic Anemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Posthemorrhagic Anemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05152641 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Acute Posthemorrhagic Anemia